Proteins are like delicate origami; if they unfold or lose their shape, they stop working. This technology acts like a molecular brace, keeping them stable and active even in harsh conditions where they would normally break down. It allows scientists to use powerful proteins that were previously too fragile for real-world use.
Many high-potential proteins for medicine and industry cannot be used because they are unstable and lose their activity outside of very specific physiological conditions.
A stabilization technology combining structural biology, molecular biology, and chemistry, including a computational design tool for predicting modification sites.
If you are a drug discovery firm dealing with protein targets for diseases with high unmet need that are too unstable to study — this project developed a stabilization technology that delivers minimally modified proteins with retained functionality.
If you are a point-of-care device manufacturer dealing with proteins that lose activity outside of a lab setting — this project developed a universal solution to stabilize proteins for biomedical applications.
If you are a chemical production plant dealing with proteins that break down during industrial processes — this project developed a technology to maintain structural integrity under non-physiological conditions.
Based on available project data, specific pricing is not mentioned, but the technology aims to replace costly and time-consuming trial-and-error stabilization approaches.
The project is currently validating the technology in a real operating environment at TRL5 to ensure it can be applied to a broad range of proteins for industrial and biomedical use.
Based on available project data, the coordinator intends to offer B2B services to customers and develop an internal drug discovery pipeline.
The project is establishing a time-efficient workflow that includes a computational tool for design and prediction of modification sites followed by a production process.
The project period runs from 2022-06-01 to 2025-05-31, focusing on reaching TRL5 validation.
The consortium is lean, consisting of 2 partners from the Netherlands and Poland. It is led by Incircular B.V., an SME, with a 50% industry ratio, combining a commercial entity with a research partner to move the technology from lab validation to a real operating environment.
Contact Incircular B.V. in the Netherlands
Contact us to explore B2B partnership opportunities with INCYPROnext.
